Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 8/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24996637 | 0.86 | ALDH1A1 (0.40) | PDE7AMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL24569945 | 0.84 | PDE7A (0.52) | PDE7AMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL29834731 | 0.84 | PDE7A (0.52) | PDE7AMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL24168260 | 0.82 | HSPB1 (0.47) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL3484788 | 0.80 | PDE7A (0.56) | PDE7AMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL24995754 | 0.79 | DYRK1A (0.42) | PDE7AKMT2AMEN1KDM4ENPC1 | |
| SCHEMBL12524904 | 0.79 | SCN5A (0.39) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2967458 | 0.74 | PDE7A (0.78) | PDE7AMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL5566489 | 0.73 | PDE7A (0.56) | PDE7AMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL11511746 | 0.73 | PDE7A (0.71) | PDE7AMAPTALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-28 | — | — | US | disclosed |
| CN-117980309-A | Tricyclic fused pyrimidine compounds useful as HER2 inhibitors | 百时美施贵宝公司 | 2024-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | ERBB2, ERBB3, EGFR | PDE7A 2287/4885MAPT 1775/4885ALDH1A1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.